Monona-based SHINE Medical Technologies has signed a long-term supply contract with GE Healthcare, its first customer. SHINE, which is still waiting for the Nuclear Regulatory Commission to approve its $85 million plant in Janesville, will manufacture molybdenum-99, which decays into technetium-99m, an isotope commonly used for diagnosing cancer and heart disease. The Janesville plant could employ about 150 people.
SHINE hopes to receive all approvals so it can build the plant and begin producing the isotope in 2017. The largest manufacturer of technetium-99m is located in Canada and will cease production in 2016.
